Free Trial

SBC Medical Group (NASDAQ:SBC) Stock Price Target Raised at BTIG Research

SBC Medical Group logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • BTIG Research raised its price target for SBC Medical Group from $8 to $10 and maintained a Buy rating, implying 36.05% upside from the prior close.
  • SBC reported quarterly earnings of $0.15 per share, beating the $0.12 consensus estimate; revenue of $58.58 million also topped forecasts of $48.90 million.
  • Analyst opinions are mixed: one rates the stock Buy and one Hold, producing a MarketBeat consensus of Moderate Buy with a $10 average price target.
  • MarketBeat previews top five stocks to own in December.

SBC Medical Group (NASDAQ:SBC - Get Free Report) had its price target hoisted by stock analysts at BTIG Research from $8.00 to $10.00 in a research report issued on Friday, Benzinga reports. The brokerage presently has a "buy" rating on the stock. BTIG Research's price target would suggest a potential upside of 36.05% from the stock's previous close.

SBC has been the topic of several other research reports. Weiss Ratings upgraded SBC Medical Group from a "hold (c-)" rating to a "hold (c)" rating in a report on Friday, October 9th. Wall Street Zen cut shares of SBC Medical Group from a "strong-buy" rating to a "buy" rating in a research note on Saturday. One investment analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $10.00.

View Our Latest Research Report on SBC

SBC Medical Group Price Performance

Shares of SBC stock opened at $7.35 on Friday. The stock's 50 day simple moving average is $5.13 and its 200 day simple moving average is $3.98. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.27 and a current ratio of 3.31. SBC Medical Group has a twelve month low of $2.78 and a twelve month high of $7.39. The company has a market capitalization of $755.93 million, a price-to-earnings ratio of 14.70, a PEG ratio of 3.30 and a beta of 0.52.

SBC Medical Group (NASDAQ:SBC - Get Free Report) last posted its earnings results on Friday, November 13th. The company reported $0.15 earnings per share for the quarter, topping the consensus estimate of $0.12 by $0.03. The firm had revenue of $58.58 million during the quarter, compared to analyst estimates of $48.90 million. SBC Medical Group had a return on equity of 19.14% and a net margin of 27.26%. As a group, research analysts predict that SBC Medical Group will post 0.44 EPS for the current year.

Hedge Funds Weigh In On SBC Medical Group

Several large investors have recently made changes to their positions in the business. Nisa Investment Advisors LLC bought a new stake in SBC Medical Group during the 3rd quarter valued at approximately $36,000. Bank of New York Mellon Corp bought a new position in SBC Medical Group in the 1st quarter worth approximately $43,000. Bank of America Corp DE acquired a new position in shares of SBC Medical Group during the second quarter worth approximately $35,000. Williams & Novak LLC lifted its holdings in shares of SBC Medical Group by 31.2% during the second quarter. Williams & Novak LLC now owns 18,686 shares of the company's stock worth $58,000 after buying an additional 4,449 shares during the last quarter. Finally, Deutsche Bank AG bought a new stake in shares of SBC Medical Group in the second quarter valued at approximately $58,000. Institutional investors and hedge funds own 60.82% of the company's stock.

SBC Medical Group Company Profile

(Get Free Report)

SBC Medical Group Holdings provides management and support services to medical institutions, with a focus on clinics offering aesthetic medicine. Its services include support for clinic operations, marketing, staff training, procurement and customer service, allowing affiliated medical providers to focus on patient care. The group is associated with the Shonan Beauty Clinic brand and a broader network of clinics offering services such as cosmetic surgery and dermatology. Its business is centered primarily in Japan, where it supports the operations and growth of affiliated medical institutions.

Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in SBC Medical Group Right Now?

Before you consider SBC Medical Group, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and SBC Medical Group wasn't on the list.

While SBC Medical Group currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines